A positive market run laid the foundation for a free trade alert in favor of PolyMedix, Inc. (OTC:PYMX) for the upcoming trading session.
Fueled by a full-blown press release, PYMX stock gained approx. 20% in value during the latest market session dated Dec. 7. Thus, PYMX closed at an 11-week high of $0.70 per share. Moreover, PYMX was also subject to very intense trade as more than 2.86 million shares of common PYMX stock changed hands by the time the trading session came to a close.
As it seems, PYMX’s latest PR which also popped up yesterday might be the driving force behind this surge. According to the update, the company has come up with fairly encouraging interim results for its Phase 2 clinical trial with PMX-30063 Defensin-Mimetic Antibiotic.
PolyMedix, Inc. is a biotechnological company that specializes in developing new therapeutic drugs aimed at treating life-threatening diseases, as well as acute cardiovascular disorders.
